MASH Pharmacotherapy Network Meta-Analysis Results Table

Mengshi Tang's dataset contains results from a network meta-analysis of 34 Phase II/III randomized controlled trials for metabolic dysfunction-associated steatohepatitis (MASH). The analysis, registered under CRD420261292638, ranks the efficacy and tolerability of pharmacological agents including SGLT2 inhibitors, FGF21 analogs, GLP-1 RAs, and THR-β agonists. The file was last updated on June 4, 2026.

Use Cases

• Ranking drug efficacy for fibrosis improvement based on relative risk (RR) values and confidence intervals
• Comparing treatment tolerability profiles based on safety outcome data from the meta-analysis
• Visualizing the benefit-risk trade-off of MASH therapies using the two-dimensional cluster analysis results
• Validating meta-analysis findings through sensitivity analyses excluding small-scale studies

Strengths

• Analysis is based on 34 studies from 33 unique publications, providing a systematic review foundation.
• Results include specific relative risk values and confidence intervals, such as RR 2.22 (95% CI 1.40-3.54) for FGF21 analogs.
• Dataset is licensed under CC-BY-4.0, permitting open sharing and reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The description notes that findings for SGLT2 inhibitors are based on limited histological data from a single pivotal trial.

Provenance

Source

figshare

Collection Method

Systematic review and network meta-analysis of trials from PubMed, Embase, Web of Science, Scopus, and Cochrane Library.

Time Range

Temporal coverage of the included trials is not specified in the description.

Freshness

Last updated 2026-06-04 04:30:34; freshness should be verified.

Geography

Spatial coverage of the included trials is not specified in the description.